Dycem
Contamination Control Floor Solutions
Cephalon has announced positive results from a Phase IV trial of Nuvigil (armodafinil) tablets for excessive sleepiness associated with shift work disorder. The six-week, double-blind and placebo-controlled study included 383 patients. Patients treated with Nuvigil showed an i
Cephalon has announced positive results from a Phase IV trial of Nuvigil (armodafinil) tablets for excessive sleepiness associated with shift work disorder.
The six-week, double-blind and placebo-controlled study included 383 patients.
Patients treated with Nuvigil showed an improvement in their condition as well as a reduction in impairment, when compared to a placebo.
The drug also improved Global Assessment of Functioning score.
The adverse affects observed with the use of Nuvigil include headache, nausea, dizziness and insomnia.
Contamination Control Floor Solutions
Crushers and Lump Breakers
Automated Handling Systems for Pre-Filled Syringes